Why these criteria exist

Gout is the most common inflammatory arthritis in adults. For clinical trials, registries, and observational studies, investigators need a standardized, reproducible definition of who counts as having gout. Older classification schemes predated widespread use of advanced imaging and performed unevenly when crystal identification was not available. The 2015 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) classification criteria for gout were developed to address that gap: they integrate clinical pattern, laboratory data, synovial fluid results when available, and imaging (ultrasound, dual-energy CT, radiography) into a transparent scoring system, with performance validated against monosodium urate (MSU) crystal identification as the reference standard in the SUGAR study cohort.

These rules are classification criteria, not a substitute for individualized diagnostic reasoning in routine care. They are most useful when you need to decide whether a patient belongs in a research cohort or when you want a structured checklist of features that increase or decrease the probability of gout in a person who has had symptomatic peripheral arthritis.

Who the criteria apply to: the entry criterion

Classification should be applied only to people who meet the entry criterion: at least one episode of swelling, pain, or tenderness in a peripheral joint or bursa. “Symptomatic episodes” in the criteria are defined around that peripheral musculoskeletal presentation. The instrument is intended for individuals with symptomatic disease; it does not classify asymptomatic hyperuricemia.

Scoring is meant to reflect the totality of the patient’s symptomatic disease experience over time, not a single flare in isolation. Domains can be accrued from information gathered at different visits, which matters for episodic conditions like gout.

The sufficient criterion: when scoring is unnecessary

If the sufficient criterion is met, the person is classified as having gout without using the numerical score. The sufficient criterion is the presence of MSU crystals in a symptomatic joint or bursa (that is, in synovial fluid from a site that has ever been symptomatic in the way defined by the entry criterion) or MSU crystals in a tophus.

In practice, this aligns with the longstanding principle that demonstration of MSU in an appropriate clinical context is a gold-standard anchor for the disease entity. When this pathway applies, you do not sum the domains below; the classification decision is already satisfied, provided the patient meets the entry criterion.

When the weighted score is used

If the sufficient criterion is not met—common when fluid was not obtained, microscopy was not performed, or results are unavailable—you apply the eight-domain scoring system. Categories within each domain are hierarchical and mutually exclusive: if, over the course of illness, a patient has qualified for more than one category in the same domain at different times, you assign the highest applicable category for that domain.

Scores are rescaled whole numbers derived from expert panel weighting and discrete-choice experiments, then simplified for usability. The maximum possible total is 23. A total score of 8 or higher fulfills the 2015 ACR/EULAR classification definition of gout among patients who meet the entry criterion and do not meet the sufficient criterion through crystal proof.

Serum urate is mandatory when using the scoring system: the published framework treats a measured serum urate value as a required element for computing the score (in contrast to domains such as imaging, where “not done” is explicitly scored like a negative/absent finding in the discrete-choice design).

Clinical domains

Pattern of joint or bursa involvement

This domain captures the anatomic pattern during symptomatic episodes that has been observed at any time. Points increase when episodes involve locations that are more characteristic of gout in the derivation data, while recognizing that ankle, midfoot, or first metatarsophalangeal (MTP) involvement can also appear in other arthritides—hence nuanced rules.

• 0 points: Involvement of joint(s) or bursa(e) other than ankle, midfoot, or first MTP, or involvement of ankle, midfoot, or first MTP only as part of a polyarticular presentation (because that pattern is less specific).
• 1 point: Ankle or midfoot as part of a monoarticular or oligoarticular episode without first MTP involvement.
• 2 points: First MTP involvement as part of a monoarticular or oligoarticular episode (the classic podagra pattern weighted most strongly in this domain).

Characteristics of symptomatic episodes

Here you count how many of three inflammatory-severity features were present during symptomatic episodes at any time (patient report or clinician observation):

• Erythema overlying the affected joint
• Inability to bear touch or pressure on the affected joint
• Great difficulty walking or inability to use the affected joint

The score rises with the number of features: 0, 1, 2, or 3 points for zero through three characteristics. This domain encodes the intensity and inflammatory phenotype of flares that experts associated with higher probability of gout in the decision analysis.

Time course of episodes

Gout flares often follow a recognizable temporal pattern. A “typical” episode in this schema requires at least two of three features, evaluated irrespective of anti-inflammatory treatment:

• Time to maximal pain in less than 24 hours
• Resolution of symptoms in 14 days or less
• Complete resolution to baseline between symptomatic episodes

Scoring distinguishes no typical episodes (0 points), a single typical episode (1 point), and recurrent typical episodes (2 points). This rewards the stereotyped, self-limited, and relapsing course that distinguishes gout from many chronic synovitides—while still allowing classification in atypical courses if other domains accumulate points.

Clinical evidence of tophus

Separate from the sufficient criterion pathway tied to crystal-proven tophus, the score includes clinical tophus as a heavily weighted feature. A tophus is defined in operational terms: for example, a draining or chalk-like subcutaneous nodule under transparent skin, often with overlying vascularity, in locations typical for urate deposition (such as joints, ears, olecranon bursa, finger pads, or tendons including the Achilles). Absent (0 points) versus present (4 points) captures the strong discriminative value of unequivocal tophaceous disease in expert judgment and validation work.

Laboratory domains

Serum urate concentration

Serum urate is measured by a uricase-based method. The criteria specify an ideal context for attribution: a value obtained when the patient is not on urate-lowering therapy and at least four weeks beyond the start of an acute episode (intercritical sampling). When that is not practicable, the framework uses the highest documented value irrespective of timing—reflecting the reality of real-world records while preserving a structured penalty for values that strongly argue against urate crystal disease.

Points by category (also expressed in mmol/L in the original tables):

• Below 4 mg/dL: −4 points (strong down-weighting)
• 4 to below 6 mg/dL: 0 points
• 6 to below 8 mg/dL: 2 points
• 8 to below 10 mg/dL: 3 points
• 10 mg/dL or higher: 4 points

Hyperuricemia is neither necessary nor sufficient for gout in clinical practice, but within this classification instrument it is integrated as a graded contributor consistent with pathophysiology and expert trade-offs.

Synovial fluid analysis from a symptomatic site

This domain applies to fluid aspirated from a joint or bursa that has been symptomatic at some point, examined by a trained observer under polarizing microscopy. If fluid was not assessed, the domain contributes 0 points. If microscopy is performed and fails to demonstrate MSU crystals, the criteria subtract 2 points from the total—one of two deliberate negative weights in the system (the other being very low serum urate).

If synovial fluid is MSU-positive, the patient should be classified through the sufficient criterion rather than through this negative scoring branch. The calculator and worksheet logic should keep those pathways distinct to avoid double interpretation.

Imaging domains

Evidence of urate deposition at a symptomatic site

Imaging must pertain to a joint or bursa that has been symptomatic at least once. Acceptable modalities in the criteria are musculoskeletal ultrasound demonstrating the double-contour sign (hyperechoic irregular enhancement over hyaline cartilage that persists with probe angle changes, distinguishing true deposition from artifact) and dual-energy CT (DECT) with appropriate acquisition parameters and gout-specific post-processing, showing color-coded urate at articular or periarticular sites. Either modality suffices; common artifacts (nail bed, submillimeter foci, skin, motion, beam hardening, vascular patterns) should not be counted as positive.

Absent or not done scores 0 points; present on either modality scores 4 points. In the underlying expert exercises, lack of imaging data was weighted similarly to negative imaging, which supports pragmatic use in settings without advanced imaging—at the cost of fewer available points from this domain.

Radiographic gout-related joint damage

Conventional radiographs of the hands and/or feet are assessed for at least one gout-related erosion, defined as a cortical break with sclerotic margin and overhanging edge. Distal interphalangeal joints and a “gull wing” appearance are excluded because they overlap with osteoarthritis morphology. Absent or not done is 0 points; present is 4 points. This domain captures chronic structural damage associated with long-standing crystal deposition—not required for classification, but highly specific when present.

Interpreting the total score

After summing all eight domains, compare the total to the prespecified threshold. Among patients who meet the entry criterion and who do not qualify via the sufficient criterion, a total of 8 or more fulfills the 2015 ACR/EULAR classification definition of gout. Totals below 8 mean the framework does not classify the individual as having gout, even though early, atypical, or partially treated disease may still be present in real clinical life.

Because negative weights exist, totals can theoretically be driven downward in scenarios combining very low serum urate with MSU-negative synovial fluid—mirroring expert consensus that those findings substantially reduce gout probability in structured classification, without claiming absolute rule-out in every patient.

Classification versus diagnosis in practice

In clinical medicine, diagnosis integrates history, examination, accessible tests, comorbidities, and treatment response. The 2015 criteria instead answer a narrower, study-oriented question: does this person meet an operational definition suitable for enrollment and comparison across centers? A patient might appropriately receive urate-lowering therapy based on clinical judgment without meeting classification, or might meet classification yet require alternative explanations considered by the treating team in an individual case.

When crystal identification is feasible, joint or tophus aspiration with competent microscopy remains central to diagnostic confidence even though the classification instrument can perform well without it in selected research analyses—reflecting trade-offs between specificity and feasibility across healthcare settings.